About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 312656, 12 pages
http://dx.doi.org/10.1155/2013/312656
Review Article

Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing

1Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain
2Department of Human Anatomy and Embryology, School of Medicine, University of Granada, 18071 Granada, Spain
3Department of Health Science, University of Jaén, 23071 Jaén, Spain

Received 4 March 2013; Revised 22 April 2013; Accepted 24 May 2013

Academic Editor: Robert Möhle

Copyright © 2013 P. Alvarez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gratwohl, H. Baldomero, O. Schmid et al., “Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003,” Bone Marrow Transplantation, vol. 36, no. 7, pp. 575–590, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Massberg and U. H. Von Andrian, “Novel trafficking routes for hematopoietic stem and progenitor cells,” Annals of the New York Academy of Sciences, vol. 1176, pp. 87–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Spradling, D. Drummond-Barbosa, and T. Kai, “Stem cells find their niche,” Nature, vol. 414, no. 6859, pp. 98–104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. H. G. Kopp, S. T. Avecilla, A. T. Hooper, and S. Rafii, “The bone marrow vascular niche: home of HSC differentiation and mobilization,” Physiology, vol. 20, no. 5, pp. 349–356, 2005. View at Scopus
  5. T. Lapidot, A. Dar, and O. Kollet, “How do stem cells find their way home?” Blood, vol. 106, no. 6, pp. 1901–1910, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Baldomero, M. Gratwohl, A. Gratwohl et al., “The EBMT activity survey 2009: trends over the past 5 years,” Bone Marrow Transplantation, vol. 46, no. 4, pp. 485–501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Gratwohl and H. Baldomero, “Trends of hematopoietic stem cell transplantation in the third millennium,” Current Opinion in Hematology, vol. 16, no. 6, pp. 420–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Cohen and A. Nagler, “Umbilical cord blood transplantation—how, when and for whom?” Blood Reviews, vol. 18, no. 3, pp. 167–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Couban, D. R. Simpson, M. J. Barnett et al., “A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies,” Blood, vol. 100, no. 5, pp. 1525–1531, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. O. Ringdén, M. Labopin, A. Bacigalupo et al., “Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 20, no. 24, pp. 4655–4664, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Z. Ratajczak, C. H. Kim, A. Abdel-Latif et al., “A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients,” Leukemia, vol. 26, no. 1, pp. 63–72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Kränkel, G. Spinettib, S. Amadesic, and P. Madedduc, “Targeting stem cell niches and trafficking for cardiovascular therapy,” Pharmacology Therapeutics, vol. 129, no. 1, pp. 62–81, 2011.
  13. T. B. Campbell, G. Hangoc, Y. Liu, K. Pollok, and H. E. Broxmeyer, “Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice,” Stem Cells and Development, vol. 16, no. 3, pp. 347–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Kawai, U. Choi, P.-C. Liu, N. L. Whiting-Theobald, G. F. Linton, and H. L. Malech, “Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells,” Stem Cells and Development, vol. 16, no. 3, pp. 361–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Haghighat, D. Weiss, M. K. Whalin, D. P. Cowan, and W. R. Taylor, “Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 115, no. 15, pp. 2049–2054, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Tura, J. Crawford, G. R. Barclay et al., “Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy,” Journal of Thrombosis and Haemostasis, vol. 8, no. 7, pp. 1614–1623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. K. Chung, E. M. Ko, S. W. Kim et al., “Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes,” Biochemistry and Molecular Biology Reports, vol. 458, no. 127, pp. 742–747, 2012.
  18. Z. H. Fu, W. Dong, L. Y. Gai, F. Wang, R. Ding, and Y. D. Chen, “Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats,” Journal of Southern Medical University, vol. 31, no. 1, pp. 17–22, 2011. View at Scopus
  19. Y. Guo, C. Liu, and J. He, “Effect of combined therapy of granulocyte colony stimulating factor and bone marrow mesenchymal stem cells carrying hepatocyte growth factor gene on angiogenesis of myocardial infarction in rats,” Chinese Journal of Reparative and Reconstructive Surgery, vol. 25, no. 6, pp. 736–740, 2011. View at Scopus
  20. L. M. Pelus, H. Bian, S. Fukuda, D. Wong, A. Merzouk, and H. Salari, “The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor,” Experimental Hematology, vol. 33, no. 3, pp. 295–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Sugiyama, H. Kohara, M. Noda, and T. Nagasawa, “Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches,” Immunity, vol. 25, no. 6, pp. 977–988, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Méndez-Ferrer, D. Lucas, M. Battista, and P. S. Frenette, “Haematopoietic stem cell release is regulated by circadian oscillations,” Nature, vol. 452, no. 7186, pp. 442–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Balabanian, B. Lagane, S. Infantino et al., “The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35760–35766, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Qing, D. Jones, and T. A. Springer, “The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment,” Immunity, vol. 10, no. 4, pp. 463–471, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Rankin, “Chemokines and adult bone marrow stem cells,” Immunology Letters, vol. 145, pp. 147–254, 2012.
  26. L. E. Perez, O. Alpdogan, J.-H. Shieh et al., “Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice,” Experimental Hematology, vol. 32, no. 3, pp. 300–307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Flomenberg, S. M. Devine, J. F. DiPersio et al., “The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone,” Blood, vol. 106, no. 5, pp. 1867–1874, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Gangadhar, S. Nandi, and R. Salgia, “The role of chemokine receptor CXCR4 in lung cancer,” Cancer Biology and Therapy, vol. 9, no. 6, pp. 409–416, 2010. View at Scopus
  29. B. A. Zabel, S. Lewén, R. D. Berahovich, J. C. Jaén, and T. J. Schall, “The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells,” Molecular Cancer, vol. 10, article no. 73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. W. C. Liles, H. E. Broxmeyer, E. Rodger et al., “Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist,” Blood, vol. 102, no. 8, pp. 2728–2730, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Wang, Y. Shiozawa, J. Wang et al., “The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer,” Journal of Biological Chemistry, vol. 283, no. 7, pp. 4283–4294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Schutyser, Y. Su, Y. Yu et al., “Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells,” European Cytokine Network, vol. 18, no. 2, pp. 59–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Dar, O. Kollet, and T. Lapidot, “Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice,” Experimental Hematology, vol. 34, no. 8, pp. 967–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Vagima, K. Lapid, O. Kollet, P. Goichberg, R. Alon, and T. Lapidot, “Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis,” Methods in Molecular Biology, vol. 750, pp. 277–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Hattori, B. Heissig, K. Tashiro et al., “Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells,” Blood, vol. 97, no. 11, pp. 3354–3360, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. D. H. Walter, U. Rochwalsky, J. Reinhold et al., “Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 275–282, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. C. H. Kim, W. Wu, M. Wysoczynski et al., “Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors,” Leukemia, vol. 26, no. 1, pp. 106–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. Lee, W. Wu, M. Wysoczynski et al., “Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes,” Leukemia, vol. 23, no. 11, pp. 2052–2062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Avigdor, P. Goichberg, S. Shivtiel et al., “CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow,” Blood, vol. 103, no. 8, pp. 2981–2989, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. I. G. Winkler and J.-P. Lévesque, “Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone,” Experimental Hematology, vol. 34, no. 8, pp. 996–1009, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J.-P. Lévesque, J. Hendy, Y. Takamatsu, B. Williams, I. G. Winkler, and P. J. Simmons, “Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment,” Experimental Hematology, vol. 30, no. 5, pp. 440–449, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. F. J. Castellino and V. A. Ploplis, “Structure and function of the plasminogen/plasmin system,” Thrombosis and Haemostasis, vol. 93, no. 4, pp. 647–654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Gong and J. Hoover-Plow, “The plasminogen system regulating stem cell mobilization,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 437920, 7 pages, 2012. View at Publisher · View at Google Scholar
  45. N. Montuori, M. V. Carriero, S. Salzano, G. Rossi, and P. Ragno, “The cleavage of the urokinase receptor regulates its multiple functions,” Journal of Biological Chemistry, vol. 277, no. 49, pp. 46932–46939, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Gazitt, “Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occuring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies,” Leukemia, vol. 18, no. 1, pp. 1–10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. C. F. Craddock, B. Nakamoto, R. G. Andrews, G. V. Priestley, and T. Papayannopoulou, “Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice,” Blood, vol. 90, no. 12, pp. 4779–4788, 1997. View at Scopus
  48. A. Chigaev, S. S. Winter, and L. A. Sklar, “Is prolonged stem cell mobilization detrimental for hematopoiesis?” Medical Hypotheses, vol. 77, no. 6, pp. 1111–1113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Ulyanova, L. M. Scott, G. V. Priestley et al., “VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin,” Blood, vol. 106, no. 1, pp. 86–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-P. Lévesque, J. Hendy, I. G. Winkler, Y. Takamatsu, and P. J. Simmons, “Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells,” Experimental Hematology, vol. 31, no. 2, pp. 109–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Kimura, B. Ding, N. Imai, D. J. Nolan, J. M. Butler, and S. Rafii, “C-kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis,” PLoS One, vol. 6, no. 10, Article ID e26918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Bonig, G. V. Priestley, V. Oehler, and T. Papayannopoulou, “Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC,” Experimental Hematology, vol. 35, no. 2, pp. 326–334, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. D. E. Wright, A. J. Wagers, A. Pathak Gulati, F. L. Johnson, and I. L. Weissman, “Physiological migration of hematopoietic stem and progenitor cells,” Science, vol. 294, no. 5548, pp. 1933–1936, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. H. E. Broxmeyer, C. M. Orschell, D. W. Clapp et al., “Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist,” Journal of Experimental Medicine, vol. 201, no. 8, pp. 1307–1318, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Heeschen, A. Aicher, R. Lehmann et al., “Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization,” Blood, vol. 102, no. 4, pp. 1340–1346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Han, Y. J. Koh, H. R. Moon et al., “Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cells,” Blood, vol. 115, no. 5, pp. 957–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. C. Pitchford, M. J. Hahnel, C. P. Jones, and S. M. Rankin, “Troubleshooting: quantification of mobilization of progenitor cell subsets from bone marrow in vivo,” Journal of Pharmacological and Toxicological Methods, vol. 61, no. 2, pp. 113–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. A. F. Cashen, D. Link, S. Devine, and J. DiPersio, “Cytokines and stem cell mobilization for autologous and allogeneic transplantation,” Current hematology reports, vol. 3, no. 6, pp. 406–412, 2004. View at Scopus
  59. R. A. Brown, D. Adkins, L. T. Goodnough et al., “Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies,” Journal of Clinical Oncology, vol. 15, no. 9, pp. 3067–3074, 1997. View at Scopus
  60. S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella, “Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy,” Journal of Clinical Oncology, vol. 18, no. 6, pp. 1360–1377, 2000. View at Scopus
  61. A. M. Greenbaum and D. C. Link, “Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization,” Leukemia, vol. 25, no. 2, pp. 211–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Cencioni, M. C. Capogrossi, and M. Napolitano, “The SDF-1/CXCR4 axis in stem cell preconditioning,” Cardiovascular Research, vol. 94, no. 3, pp. 400–407, 2012.
  63. U. Duhrsen, J. L. Villeval, J. Boyd, G. Kannourakis, G. Morstyn, and D. Metcalf, “Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients,” Blood, vol. 72, no. 6, pp. 2074–2081, 1988. View at Scopus
  64. F. Lefrère, M. Bernard, F. Audat et al., “Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients,” Leukemia and Lymphoma, vol. 35, no. 5-6, pp. 501–505, 1999. View at Scopus
  65. J. C. Fischer, M. Frick, R. Wassmuth, A. Platz, M. Punzel, and P. Wernet, “Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors,” British Journal of Haematology, vol. 130, no. 5, pp. 740–746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. L. B. To, J.-P. Levesque, and K. E. Herbert, “How I treat patients who mobilize hematopoietic stem cells poorly,” Blood, vol. 118, no. 17, pp. 4530–4540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. I. H. Motabi and J. F. DiPersio, “Advances in stem cell mobilization,” Blood Reviews, vol. 26, no. 6, pp. 267–278, 2012.
  68. S. Fruehauf, K. Schmitt, M. R. Veldwijk et al., “Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients,” British Journal of Haematology, vol. 105, no. 3, pp. 786–794, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Mohty and A. D. Ho, “In and out of the niche: perspectives in mobilization of hematopoietic stem cells,” Experimental Hematology, vol. 39, no. 7, pp. 723–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Bensinger, F. Appelbaum, S. Rowley et al., “Factors that influence collection and engraftment of autologous peripheral-blood stem cells,” Journal of Clinical Oncology, vol. 13, no. 10, pp. 2547–2555, 1995. View at Scopus
  71. M. A. Gertz, R. C. Wolf, I. N. M. Micallef, and D. A. Gastineau, “Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma,” Bone Marrow Transplantation, vol. 45, no. 9, pp. 1396–1403, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. R. T. Maziarz, A. P. Nademanee, I. N. Micallef et al., “Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells,” Biology of Blood and Marrow Transplantation, vol. 19, no. 4, pp. 670–675, 2013.
  73. S. Hashimoto, M. Itoh, M. Nishimura, and T. Asai, “Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells,” Therapeutic Apheresis, vol. 6, no. 6, pp. 431–436, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Kröger, H. Renges, W. Krüger et al., “A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation,” British Journal of Haematology, vol. 111, no. 3, pp. 761–765, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. S. J. Ings, C. Balsa, D. Leverett, S. Mackinnon, D. C. Linch, and M. J. Watts, “Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used,” British Journal of Haematology, vol. 134, no. 5, pp. 517–525, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. P. S. Becker, M. Wagle, S. Matous et al., “Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells,” Biology of Blood and Marrow Transplantation, vol. 3, no. 1, pp. 45–49, 1997. View at Scopus
  77. A. P. Dincer, J. Gottschall, and D. A. Margolis, “Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization,” Journal of Pediatric Hematology/Oncology, vol. 26, no. 11, pp. 761–763, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Z. Ratajczak, H. Lee, M. Wysoczynski et al., “Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex,” Leukemia, vol. 24, no. 5, pp. 976–985, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. W. P. Sheridan, C. G. Begley, C. A. Juttner et al., “Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy,” Lancet, vol. 339, no. 8794, pp. 640–644, 1992. View at Publisher · View at Google Scholar · View at Scopus
  80. L. S. Schwartzberg, R. Birch, B. Hazelton et al., “Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor,” Journal of hematotherapy, vol. 1, no. 4, pp. 317–327, 1992. View at Scopus
  81. C. Dazzi, A. Cariello, G. Rosti et al., “Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?” Leukemia and Lymphoma, vol. 39, no. 3-4, pp. 301–310, 2000. View at Scopus
  82. D. Dingli, G. S. Nowakowski, A. Dispenzieri et al., “Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma,” Clinical Lymphoma and Myeloma, vol. 6, no. 5, pp. 384–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Kim, H.-J. Kim, J. S. Park et al., “Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma,” Annals of Hematology, vol. 84, no. 11, pp. 742–747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Hosing, R. M. Saliba, S. Ahlawat et al., “Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma,” American Journal of Hematology, vol. 84, no. 6, pp. 335–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Kuittinen, T. Nousiainen, P. Halonen, E. Mahlamäki, and E. Jantunen, “Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma,” Bone Marrow Transplantation, vol. 33, no. 9, pp. 907–912, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. P. Wuchter, D. Ran, T. Bruckner et al., “Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation,” Biology of Blood and Marrow Transplantation, vol. 16, no. 4, pp. 490–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Olivieri, M. Marchetti, R. Lemoli et al., “Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo,” Bone Marrow Transplantation, vol. 47, no. 3, pp. 342–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. I. Petit, M. Szyper-Kravitz, A. Nagler et al., “G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4,” Nature Immunology, vol. 3, no. 7, pp. 687–694, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. W. Bensinger, J. F. DiPersio, and J. M. McCarty, “Improving stem cell mobilization strategies: future directions,” Bone Marrow Transplantation, vol. 43, no. 3, pp. 181–195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. T. Demirer, C. D. Buckner, T. Gooley et al., “Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma,” Bone Marrow Transplantation, vol. 17, no. 6, pp. 937–941, 1996. View at Scopus
  91. I. Pusic, S. Y. Jiang, S. Landua et al., “Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation,” Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 1045–1056, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. E. Jantunen, M. Itälä, T. Siitonen et al., “Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis,” Bone Marrow Transplantation, vol. 41, no. 3, pp. 239–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Haas, R. Möhle, S. Frühauf et al., “Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma,” Blood, vol. 83, no. 12, pp. 3787–3794, 1994. View at Scopus
  94. D. Lysak, V. Koza, K. Steinerova, P. Jindra, V. Vozobulova, and M. Schutzova, “Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment,” Annals of Hematology, vol. 84, no. 7, pp. 456–461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Laszlo, P. Galieni, D. Raspadori, M. Tozzi, F. Lauria, and G. Martinelli, “Fludarabine combination regimen severely affected peripheral blood stem cell mobilization,” Acta Haematologica, vol. 111, no. 4, pp. 228–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. U. Popat, R. Saliba, R. Thandi et al., “Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 15, no. 6, pp. 718–723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Sevilla, M. Guillén, A. Castillo et al., “Defining “poor mobilizer” in pediatric patients who need an autologous peripheral blood progenitor cell transplantation,” Cytotherapy, vol. 15, no. 1, pp. 132–137, 2013.
  98. X. Han, L. Ma, L. Zhao et al., “Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study,” Journal of Clinical Apheresis, vol. 27, no. 2, pp. 64–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Fu, R. K. Bagai, H. Meyerson et al., “Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization,” Bone Marrow Transplantation, vol. 38, no. 3, pp. 189–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Suzuya, T. Watanabe, R. Nakagawa et al., “Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors,” Vox Sanguinis, vol. 89, no. 4, pp. 229–235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. A. C. Zubair, R. Grant, W. Wu et al., “Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients,” Transfusion, vol. 48, no. 6, pp. 1106–1114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Molineux, Z. Pojda, I. N. Hampson, B. I. Lord, and T. M. Dexter, “Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor,” Blood, vol. 76, no. 10, pp. 2153–2158, 1990. View at Scopus
  103. L. N. Gordan, M. W. Sugrue, J. W. Lynch et al., “Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation,” Leukemia and Lymphoma, vol. 44, no. 5, pp. 815–820, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Ferraro, S. Lymperi, S. Méndez-Ferrer et al., “Diabetes impairs hematopoietic stem cell mobilization by altering niche function,” Science translational medicine, vol. 3, no. 104, article 104ra101, 2011. View at Scopus
  105. D. Lysák, M. Hrabětová, J. Vrzalová et al., “Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance,” Transfusion, vol. 51, no. 2, pp. 319–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. A. F. Cashen, B. Nervi, and J. DiPersio, “AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent,” Future Oncology, vol. 3, no. 1, pp. 19–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. S. M. Devine, N. Flomenberg, D. H. Vesole et al., “Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 22, no. 6, pp. 1095–1102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. R. F. Duarte, B. E. Shaw, P. Marín et al., “Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data,” Bone Marrow Transplantation, vol. 46, no. 1, pp. 52–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. W. C. Liles, E. Rodger, H. E. Broxmeyer et al., “Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist,” Transfusion, vol. 45, no. 3, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. K. W. Douglas, A. N. Parker, P. J. Hayden et al., “Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA,” Bone Marrow Transplantation, vol. 47, no. 1, pp. 18–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Abhyankar, S. Dejarnette, O. Aljitawi, S. Ganguly, D. Merkel, and J. McGuirk, “A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor,” Bone Marrow Transplantation, vol. 47, no. 4, pp. 483–487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. M. R. Kessans, M. L. Gatesman, and D. R. Kockler, “Plerixafor: a peripheral blood stem cell mobilizer,” Pharmacotherapy, vol. 30, no. 5, pp. 485–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. E. Jantunen, “Novel strategies for blood stem cell mobilization: special focus on plerixafor,” Expert Opinion on Biological Therapy, vol. 11, no. 9, pp. 1241–1248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Cashen, S. Lopez, F. Gao et al., “A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 11, pp. 1253–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Calandra, J. McCarty, J. McGuirk et al., “AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data,” Bone Marrow Transplantation, vol. 41, no. 4, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. I. N. Micallef, P. J. Stiff, J. F. DiPersio et al., “Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin Lymphoma: results from the plerixafor NHL phase 3 study rescue protocol,” Biology of Blood and Marrow Transplantation, vol. 15, no. 12, pp. 1578–1586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Steinberg and M. Silva, “Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin's lymphoma or multiple myeloma,” Clinical Therapeutics, vol. 32, no. 5, pp. 821–843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. P. Stiff, I. Micallef, P. McCarthy et al., “Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient,” Biology of Blood and Marrow Transplantation, vol. 15, no. 2, pp. 249–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Jantunen and G. Kvalheim, “Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies,” European Journal of Haematology, vol. 85, no. 6, pp. 463–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. M. J. Dugan, R. T. Maziarz, W. I. Bensinger et al., “Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 39–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Yannaki, T. Papayannopoulou, E. Jonlin et al., “Hematopoietic stem cell mobilization for gene therapy of adult patients with severe Β-thalassemia results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects,” Molecular Therapy, vol. 20, no. 1, pp. 230–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. C. Saure, C. Weigelt, T. Schroeder et al., “Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer,” Acta Haematologica, vol. 124, no. 4, pp. 235–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Sinha, D. Gastineau, I. Micallef et al., “Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention,” Bone Marrow Transplantation, vol. 46, no. 7, pp. 943–949, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. F. T. Awan, S. T. Kochuparambil, D. Deremer et al., “Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and Filgrastim-based peripheral blood progenitor cell mobilization,” Journal of Oncology, vol. 2012, Article ID 931071, 5 pages, 2012. View at Publisher · View at Google Scholar
  125. F. Zohren, D. Toutzaris, V. Klärner, H.-P. Hartung, B. Kieseier, and R. Haas, “The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans,” Blood, vol. 111, no. 7, pp. 3893–3895, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Bonig, A. Wundes, K.-H. Chang, S. Lucas, and T. Papayannopoulou, “Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab,” Blood, vol. 111, no. 7, pp. 3439–3441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Schmitt, N. Weinhold, K. Dembowsky, et al., “First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HCS) in multiple myeloma (MM),” Blood, vol. 116, abstract 824, no. 21, Proceedings of the ASH Annual Meeting Abstracts, 2010.
  128. A. Nagler, A. Shimoni, I. Avivi et al., “BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation,” Blood, vol. 116, abstract 2260, no. 21, Proceedings of the ASH Annual Meeting Abstracts, 2010.
  129. S. K. Ghadge, S. Mühlstedt, C. Özcelik, and M. Bader, “SDF-1α as a therapeutic stem cell homing factor in myocardial infarction,” Pharmacology and Therapeutics, vol. 129, no. 1, pp. 97–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Wang and K. Luther, “Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway,” Progress in Molecular Biology and Translational Science, vol. 111, pp. 265–284, 2012.
  131. Z. Wen, S. Zheng, C. Zhou, J. Wang, and T. Wang, “Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction,” Journal of Cellular and Molecular Medicine, vol. 15, no. 5, pp. 1032–1043, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. A. V. Karapetyan, Y. M. Klyachkin, S. Selim et al., “Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow derived stem cell in patients with acute myocardial infarction,” Stem Cells and Development, vol. 22, no. 11, pp. 1645–1656, 2013. View at Publisher · View at Google Scholar
  133. Z. Wen, S. Zheng, C. Zhou, W. Yuan, J. Wang, and T. Wang, “Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators,” Journal of Cellular and Molecular Medicine, vol. 16, no. 4, pp. 657–671, 2012.
  134. S. J. Hong, S. C. Choi, J. S. Kim et al., “Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation,” Heart, vol. 96, no. 10, pp. 756–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Harada, Y. Qin, H. Takano et al., “G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes,” Nature Medicine, vol. 11, no. 3, pp. 305–311, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. D. Zohlnhöfer, I. Ott, J. Mehilli et al., “Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial,” Journal of the American Medical Association, vol. 295, no. 9, pp. 1003–1010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. T. B. Campbell, A. Sevin, R. W. Coombs et al., “Changes in human immunodeficiency virus type 1 virus lead during mobilization and harvesting of hemopoietic progenitor cells,” Blood, vol. 95, no. 1, pp. 48–55, 2000. View at Scopus
  138. R. T. Schooley, J. Mladenovic, A. Sevin et al., “Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease,” Journal of Infectious Diseases, vol. 181, no. 1, pp. 148–157, 2000. View at Publisher · View at Google Scholar · View at Scopus